260 in- and outpatients suffering from schizophrenia were included in a therapy study with Risperidone. The mean daily dose amounted to 3.9 mg. The mean treatment periode was 104 days (s.d. +/- 61). Patients showed a statistically significant decrease in the rating scales used (CGI, BPRS, PANSS). Risperidone was very well tolerated, only 4.2% of the patients had to be withdrawn due to side effects. Another important result of the study presented is, that extrapyramidal motoric symptoms decreased significantly during the treatment with Risperidone. Rispsridone proved to be effective in schizophrenic patients against positive as well as negative symptoms and showed a favourable side effect profile.